- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Prevalence of Cutaneous Squamous Cell Carcinoma (CSCC) & Basal Cell Carcinoma (BCC)
Panelists discuss the current prevalence and treatment landscape of cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC).
EP: 1.Prevalence of Cutaneous Squamous Cell Carcinoma (CSCC) & Basal Cell Carcinoma (BCC)
EP: 2.Immunotherapy Landscape in cSCC and BCC
EP: 3.Immunotherapy and Radiation Therapy in cSCC and BCC
EP: 4.Immunotherapy Barriers: Multidisciplinary Approach in cSCC and BCC
EP: 5.Coordination of Care: Interdisciplinary Immunotherapy Challenges in Nonmelanoma Skin Cancers
EP: 6.Multidisciplinary Collaboration: Best Practices for CSCC and BCC Management
EP: 7.Dermatologists and Immunotherapy: Managing Patient Expectations
EP: 8.Monitoring Immunotherapy Toxicities in CSCC and BCC
EP: 9.Staging Disease and Risk Stratification in CSCC and BCC
EP: 10.Targeted Therapy: Hedgehog Inhibitors in BCC
EP: 11.Socioeconomic Implications of CSCC and BCC
EP: 12.Immunosuppression in CSCC and BCC Treatment
EP: 13.Updates in Therapeutics for Nonmelanoma Skin Cancers
EP: 14.Concluding Thoughts on the Future of CSCC and BCC Care
This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; Christopher Barker, MD; Omid Hamid, MD; Vishal Patel, MD; and Catherine Pisano, MD.
Patel provided an overview of cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC), the 2 most common types of nonmelanoma skin cancer. He explained that cSCC and BCC arise from keratinocytes in the epidermis and can present as rough, scaly patches or nodules that continue to grow and won’t heal. Pisano highlighted that cSCC and especially BCC are extremely common, with incidence rising as the population ages. She noted that cSCCis responsible for more cancer deaths annually than melanoma or Merkel cell carcinoma. Hamid then discussed immunotherapy with PD-1 inhibitors as a new standard of care for advanced cSCC and BCC. Hamid concluded that immunotherapy not only drives responses in advanced keratinocyte carcinomas but exhibits durability that could form the backbone of future combination regimens.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Gene Therapy Enhances Visual Processing for Inherited Retinal Disease
December 3rd 2024Gene therapy partially restores visual processing in the geniculostriate pathway of patients with Leber congenital amaurosis type 2 while maintaining compensatory activity in the retinotectal pathway.
Read More
New Guidelines Clarify EORTC Quality of Life Scores for Chronic Lymphocytic Leukemia
December 2nd 2024Meaningful change thresholds for the EORTC Quality of Life Questionnaire in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are: −11/+11 for symptom burden, −16/+16 for physical condition/fatigue, and −16/+13 for worries/fears.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
sGFAP May Predict Progression Independent of Relapse in BCDT-Treated MS
November 29th 2024The findings show that increases in serum glial fibrillary acidic protein throughout B-cell depletion therapy are associated with disability worsening despite not relapsing—known as progression independent of relapse activity.
Read More
